Please login to the form below
ulcerative colitis
This page shows the latest ulcerative colitis news and features for those working in and with pharma, biotech and healthcare.
Celgene to launch five new products through to 2020
The company is also trying to extend use of Otezla into additional indications, and despite reporting mixed phase 2 data in ulcerative colitis earlier this year has moved ahead with a
Latest news
-
BMS CEO tackles investor ‘frustrations’ on immuno-oncology
s disease, ulcerative colitis and lupus.
-
Gilead and Galapagos JAK contender scores in RA trial
The results are further good news for the partners and their inflammatory conditions contender, which is also being studied in ulcerative colitis, Crohn’s disease and ankylosing spondylitis.
-
Gilead, Galapagos JAK inhibitor clears phase II test
The drug is also in development for rheumatoid arthritis (RA), ulcerative colitis and Crohn’s disease with phase III trials already underway in those indications and results due in the coming ... Like filgotinib, upadacitinib is also being tested in a
-
Immunology keeps Shire figures solid as Takeda takeover nears
There were gains for newer products Entyvio (vedolizumab) or ulcerative colitis, up a third to around $550m, and myeloma therapy Ninlaro (ixazomib) which climbed 43% to $125m, but Takeda is predicting
-
Communiqué: big wins for obesity and sugar tax campaigners
This entry described a live ‘broadcast’meeting that provided education around excess steroid use, a standard treatment for ulcerative colitis. ... Meanwhile, Aurora Healthcare Communications’ Travel with IBD campaign for Japanese pharma group
More from news
Approximately 19 fully matching, plus 111 partially matching documents found.
Latest Intelligence
-
Taking a lean and careful approach
ulcerative colitis, type 1 diabetes and inflammatory bowel disease.
-
Making digital health personal
Personalisation: A case study. This case study is of a digital health support programme that improved persistence of people with ulcerative colitis.
-
Deal Watch January 2017
Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative colitis (ABI-M201) and Crohn's disease plus 2 compounds for IBS.
-
Forging a path in specialty care
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
-
Biosimilars - the same, but different?
The first months of 2015 also saw it approve Remsima and Inflectra for use on the NHS to treat moderately to severely active ulcerative colitis after the failure of conventional therapy.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Lorin Johnson joins Atlantic Healthcare board
Atlantic's lead asset, alicaforsen for the treatment of the inflammatory bowel diseases ulcerative colitis and pouchitis.
-
Ex J&J VP joins board of Immune
Its lead product candidate is bertilimumab, which is in clinical development for ulcerative colitis and Crohn's Disease as well as the rare skin condition bullous pemphigoid.
-
AstraZeneca veteran Deborah Hartman joins Avaxia
AstraZeneca veteran Deborah Hartman joins Avaxia. Will lead the development of AVX-470 in ulcerative colitis. ... with active ulcerative colitis.
-
EMA’s Pharmacovigilance Risk Assessment Committee gains new members
Their respective alternates are Kirsten Myhr, from the Norwegian Board of Health, and Marco Greco, from the European Federation Crohn's and Ulcerative Colitis Associations.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Smart Pill Technologies Market: Global Industry Analysis and Opportunity Assessment by 2025
Prevalence of Crohn's disease is 201 per 100, 000 adults and Ulcerative colitis is 238 per 100, 000 adults. ... The rising geriatric population will also act as a driver since this segment of population is more prone to IBD, Ulcerative colitis and
-
News: Research Partnership launches new patient report - Living with Ulcerative Colitis
News: Research Partnership launches new patient report - Living with Ulcerative Colitis. ... Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017
Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017. ... Living with Ulcerative Colitis (UC) is a study conducted amongst 110 adult UC patients in the US.
-
Research Partnership launches new patient Living with Ulcerative Colitis (UC) US report
Research Partnership launches new patient Living with Ulcerative Colitis (UC) US report. ... Living with Ulcerative Colitis (UC) is a study conducted amongst 100 adult UC patients in the US.
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016
Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016. ... Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe.
More from PMHub
Approximately 5 fully matching, plus 3 partially matching documents found.
Featured jobs
-
New Business Director - PR
-
Competitive Salary and benefits
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Senior Medical Writer
-
Great salary and benefits
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
- Senior Account Executive, London, Medical Communications
-
Excellent package
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Account Director
-
Excellent benefits
-
Medical Writers
-
Competitive Salary and Benefits
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
-
Associate Director
-
£75, 000-90, 000
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Consumer Health Account Director
-
Circa £60, 000 Gym and More
-
Senior Account Manager
-
Negotiable
- Director, Market Access / HEOR - North-West
-
Negotiable
- Senior Account Director development role to Business Director, H...
-
Excellent package
Subscribe to our email news alerts
- Cranial Closure And Fixation Devices Market to Reflect Steady Growth Rate by 2026
- Brain Cancer Diagnostics Market Investment Research Report 2016-2026
- Healthcare sector bullish despite political uncertainty
- Bioprocessing Analytics Equipment Market is anticipated to register a CAGR of 4.5% over the forecast period 2028
- Behavioural Health Market is expected to expand at 3.4% CAGR over the forecast period 2018-2028.
- Prurigo Nodularis Treatment Market is poised to expand at 3.4% CAGR over the forecast period of 2018–2028
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...
Latest intelligence
- Innovation in merger control and the impact on the pharmaceutical sector
- Is focusing on pipeline products enough to assess regulatory risks?...
- Nudge-nudge, think-think
- Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
- Quality in Care Diabetes 2018: the best in innovative diabetes care
- Awards highlight new evidence-based approaches to improving care...
Quick links
Infographics
